BioSpace News Archive

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced positive interim data from the ongoing Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors.

As Canada’s Chief Public Health Officer, it is a priority for me that Canadians are equipped with accurate and evidence-based information in order to make well-informed decisions about their health.

In the wake of the novel coronavirus pandemic, the need for reliable, accurate, and accessible laboratory testing is more evident than ever before.

Artificial intelligence has the potential to revolutionize healthcare, but integrating AI-based techniques into routine medical practice has proven to be a significant challenge.

A new study shows that a first-of-its-kind rapid test could identify which COVID-19 patients are responding to drug treatments and which patients are still deteriorating and need higher doses of medication.

The opioid epidemic has only gotten worse since the advent of COVID-19, with some areas in the U.S. reporting a 50% increase in drug overdoses due to the pandemic.

During the all-virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo, leading scientific experts will dive into the groundbreaking advances that are the future of cancer care.

AACC is pleased to announce the recipients of the AACC 2020 Top Corporate Supporter Awards.

South Korea’s biotechnology company specializing in molecular diagnosis, Seegene Inc., announced Monday that its aggregated sales this year have already surpassed the KRW 1 trillion mark, up nearly 10 times its previous annual sales of KRW 120 billion in 2019.

Junshi Biosciences is pleased to announce that the Independent Data Monitoring Committee has determined that Toripalimab in combination with standard chemotherapy as the first-line treatment of patients with advanced non-small cell lung cancer has reached its pre-specified primary endpoint of Progression Free Survival at the interim analysis of a randomized, double-blind, multi-center, phase III clinical study “CHOICE-01”.